When was VitaDX founded?

VitaDX was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is VitaDX located?

VitaDX is headquartered in Evry Courcouronnes, France.

How many employees does VitaDX have?

As of Jul 01, 2024, the latest employee count at VitaDX is 25.

Is VitaDX a funded company?

VitaDX is a funded company, having raised a total of $23.3M across 10 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 16, 2015.

When was the latest funding round of VitaDX?

VitaDX's latest funding was a $***** Series B round on Aug 22, 2025, with participation from 2 investors. Its primary sector is Oncology. In France, the Oncology sector has seen $62.7M in funding in 2026 to date.

Where does VitaDX rank among its competitors?

VitaDX ranks 1st amongst 18 active competitors, of which 9 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was VitaDX, which secured $1.74M in Aug, 2025.

Who are the top competitors of VitaDX?

VitaDX's top competitors include Nucleix, ArquerDx and OncoDiag. Among them, VitaDX secured the most recent funding round in August, 2025.

VitaDX - 2026 Company Profile, Team, Funding & Competitors

Company Details

VitaDx develops early diagnostics for bladder cancer. The company uses a proprietary protocol that uses digital analysis to analyze urine and detect selective fluorescence around bladder cancer cells. VitaDx claims that this fluorescence detects cells with greater accuracy and sensitivity than traditional staining protocols, even in early stages of the disease.

Website: vitadx.com
Phone Number: +33 **********

Key Metrics

Founded Year

2015

Location

Evry Courcouronnes, France

Stage

Series B

Total Funding

$23.3M in 10 rounds

Latest Funding Round

Series B, Aug 22, 2025, $*****

Investors

Odyssee Venture & 11 more

Ranked

1^st among 18 active competitors

Employee Count

25 as on Jul 01, 2024

Similar Companies

Nucleix & 21 more

View VitaDX's full profile

VitaDX has raised a total funding of $23.3M over 10 rounds. Its first funding round was on Jun 16, 2015. Its latest funding round was a Series B round on Aug 22, 2025 for $*****. 2 investors participated in its latest round. VitaDX has 11 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of VitaDX:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 22, 2025	4627663	Series B	3207553	9317058	2276022	6772566
Oct 08, 2024	6840817	Series B	4196205	5654891	2741834	7984850
Apr 2024	1364543	Series A	8660636	4964584	9418466	3106856

Access funding benchmarks and valuations. Sign up today!

View details of VitaDX's funding rounds and investors

The founders of VitaDX is Thibaut Troude. Allan Rodriguez is the CEO of VitaDX.

Here are the details of VitaDX's key team members:

Thibaut Troude: Co-Founder & CTO of VitaDX.
Contact Info: 1 email address
Allan Rodriguez: CEO of VitaDX.

View details of VitaDX's Founder profiles and Board Members

VitaDX's employee count trend

VitaDX has 25 employees as of Jul 24. Here is VitaDX's employee count trend over the years:

Uncover VitaDX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VitaDX include Nucleix, ArquerDx and OncoDiag. Here is the list of Top 10 competitors of VitaDX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	VitaDX 2015, Evry Courcouronnes (France), Series B	Early diagnostics for bladder cancer	$23.3M	Auriga Partners, Caisse D Epargne & 10 others	60/100
2nd	Nucleix 2008, Rehovot (Israel), Series C	Developer non-invasive molecular cancer diagnostic tests	$88.5M	RA Capital Management, Sands Capital & 10 others	50/100
3rd	ArquerDx 2007, Sunderland (United Kingdom), Series A	Develops urine-based immunoassay tests for genitourinary cancers.	$5.38M	North East Fund, Cambridge Capital Group ... & 84 others	38/100
4th	OncoDiag 2013, Miserey (France), Series A	Developer of non-invasive cancer diagnostic solutions	$4.2M	Angels Sante, Paris Business Angels & 3 others	36/100
5th	Early Is Good 2019, Indianapolis (United States), Seed	Developer of multi-omic platform for biomarker detection to transform healthcare	$4M	Social Capital, HHS	33/100
6th	Sienna Diagnostics 2002, Scoresby (Australia), Public	Developer of in-vitro diagnsotics tests for the detection of cancer	$3.05M	-	33/100
7th	Cellens 2020, Medford (United States), Series A	Developer of non-invasive diagnostic technology for the detection of bladder cancer	$6.94M	IndieBio	32/100
8th	KDx Diagnostics 2016, Los Gatos (United States), Seed	Provider of urine and bladder test to detect cancer	$1.12M	-	32/100
9th	InnoTech Precision Medicine 2021, Boston (United States), Funding Raised	Developer of multimodal molecular diagnostic platform for early disease detection	-	HHS	31/100
10th	Matritech 1996, Newton (United States), Acquired	Protein-based point-of-care diagnostic tests	-	Zero Stage Capital, Tekla Capital Management ... & 1 others	30/100